FibroBiologics, Inc. (Nasdaq: FBLG), a biotechnology company based in Houston, has stated that they anticipate the current supply to be adequate for the clinical trial. The company, known for their focus on innovative treatments, holds over 270 patents. This approach is aimed at reducing costs and ensuring the completion of the trial successfully. The news was released on July 7, 2026.